01.12.2025

There has been a recent update on givinostat, a potential treatment for Duchenne muscular dystrophy, which is currently being assessed for use on the NHS in England.

Givinostat has shown promising results in clinical trials, where it has helped slow the progression of Duchenne. This could make a meaningful difference for children and families living with the condition.

At the moment, givinostat is being reviewed by the National Institute for Health and Care Excellence (NICE), the body responsible for deciding which treatments should be available through the NHS in England. Following their first meeting on 10 July 2025, the committee has asked for more evidence before making a final decision.

While it is common for NICE to either recommend a treatment or request further discussion at this stage, in this case, they have asked for additional evidence before deciding. This means a final decision has not yet been made. Although this may feel frustrating for families waiting for progress, gathering robust evidence is an important part of ensuring treatments are safe, effective, and accessible in the long term.

For the latest updates on givinostat and other research developments, we recommend visiting the Muscular Dystrophy UK news page, where information is regularly updated.